cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-23. Numbers and descriptions here follow the published literature rather than marketing material.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
The adrenergic receptors were discovered Henry Hallett Dale in 1906 and the α- and β-adrenergic receptors were differentiated by Raymond P. Ahlquist in 1948. In 1967, the β-adrenergic receptors were further differentiated into the β1- and β2-adrenergic receptors by Alonzo M. Lands. The first beta blocker to be developed was dichloroisoprenaline, based on structural modification of the β-adrenergic receptor agonist isoprenaline (isoproterenol). It was described by C. E. Powell and I. H. Slater in 1958. However, dichloroisoprenaline had significant partial agonism and sympathomimetic activity and hence was not a pure antagonist. James Black and John Stephenson described pronethalol (nethalide; ICI-38,174; Alderlin) as a purely antagonistic beta blocker in 1962. But pronethalol suffered from off-target activity and associated side effects and toxicity. As such, it did not enter widespread use and was soon discontinued. In 1964, Black and colleagues published on propranolol (ICI-45,520; Inderal), which did not have the problems of earlier beta blockers. It was introduced for medical use under the brand name Inderal the same year and became the first widely used beta blocker. Since the introduction of propranolol, there have been three generations of beta blockers with different pharmacological properties, with numerous beta blockers having been developed and introduced for medical use.
== Research == (2R,6R)-HNK is under development by the National Institute of Mental Health (NIMH) in the United States for the treatment of depression. As of late 2019, it is in phase I clinical trials for this indication. It is also under development under the developmental code name SPL-801-B by Cybin for depressive disorders.
== List of anorectics == Numerous pharmaceutical compounds are marketed as appetite suppressants. The following drugs are listed as "centrally-acting antiobesity preparations" in the Anatomical Therapeutic Chemical Classification System:
Sources: en.wikipedia.org
=== Variation === The lobes of the lung are subject to anatomical variations. A horizontal interlobar fissure was found to be incomplete in 25% of right lungs, or even absent in 11% of all cases. An accessory fissure was also found in 14% and 22% of left and right lungs, respectively. An oblique fissure was found to be incomplete in 21% to 47% of left lungs. In some cases a fissure is absent, or extra, resulting in a right lung with only two lobes, or a left lung with three lobes. A variation in the airway branching structure has been found specifically in the central airway branching. This variation is associated with the development of COPD in adulthood.
The "inert" or noble gas elements (helium, neon, argon, krypton, xenon and radon) are composed of lone atoms as their smallest discrete unit, but the other isolated chemical elements consist of either molecules or networks of atoms bonded to each other in some way. Identifiable molecules compose familiar substances such as water, air, and many organic compounds like alcohol, sugar, gasoline, and the various pharmaceuticals. However, not all substances or chemical compounds consist of discrete molecules, and indeed most of the solid substances that make up the solid crust, mantle, and core of the Earth are chemical compounds without molecules. These other types of substances, such as ionic compounds and network solids, are organized in such a way as to lack the existence of identifiable molecules per se. Instead, these substances are discussed in terms of formula units or unit cells as the smallest repeating structure within the substance. Examples of such substances are mineral salts (such as table salt), solids like carbon and diamond, metals, and familiar silica and silicate minerals such as quartz and granite. One of the main characteristics of a molecule is its geometry often called its structure. While the structure of diatomic, triatomic or tetra-atomic molecules may be trivial, (linear, angular pyramidal etc.) the structure of polyatomic molecules, that are constituted of more than six atoms (of several elements) can be crucial for its chemical nature.
Xi's position as the apparent successor to become the paramount leader was threatened with the rapid rise of Bo Xilai, the party secretary of Chongqing at the time. Bo was expected to join the PSC after the 18th Party Congress, with most expecting that he would try to eventually maneuver himself into replacing Xi. Bo's policies in Chongqing inspired imitations throughout China and received praise from Xi himself during Xi's visit to Chongqing in 2010. Records of praises from Xi were later erased after he became paramount leader. Bo's downfall would come with the Wang Lijun incident, which opened the door for Xi to come to power without challengers. On 18 October 2010, at the fifth plenary session of the 17th Central Committee, Xi was elected to be a vice chairman of the CCP Central Military Commission, followed by his appointment as vice chairman of the state CMC on 28 October by the Standing Committee of the National People's Congress. A few months before his ascendancy to the party leadership, Xi disappeared from official media coverage and cancelled meetings with foreign officials for several weeks beginning on 1 September 2012, causing rumors. He then reappeared on 15 September. On 15 November 2012, immediately after the 18th Party National Congress, Xi was elected by the first plenary session the 18th Central Committee to the posts of Party general secretary and chairman of the Party CMC. This made him both the CCP leader and, informally, China's paramount leader. The following day Xi led the new line-up of the PSC onto the stage in their first public appearance.
Sources: en.wikipedia.org
In Blood Diamond, DiCaprio starred as a diamond smuggler from Rhodesia who is involved in the Sierra Leone Civil War. While filming, he worked with 24 orphaned children from the SOS Children's Village in Maputo, Mozambique, and said he was touched by his interactions with them. To prepare, he spent six months in Africa, learned about camouflage from people in South African military and interviewed and recorded people in the country to improve his accent. The film received generally favorable reviews, and DiCaprio was noted for his South African accent, which is generally known as difficult to imitate. Claudia Puig of the USA Today approvingly highlighted DiCaprio's transition from a boy to a man on screen, and Ann Hornaday of The Washington Post similarly noted his growth as an actor since The Departed. DiCaprio received nominations for an Academy Award and a Golden Globe for Blood Diamond. In 2007, DiCaprio produced the comedy drama Gardener of Eden, which according to The Hollywood Reporter's Frank Scheck "lack[ed] the necessary dramatic urgency or black humor to connect with audiences". Later that year, he produced, co-wrote and narrated The 11th Hour, a documentary on the state of the natural environment that won the Earthwatch Environmental Film Award in 2008. DiCaprio's Appian Way produced Planet Green's Greensburg (2008–2010), which ran for three seasons. Set in Greensburg, Kansas, it is about rebuilding the town in a sustainable way after being hit by the 2007 Greensburg tornado.
== Taxonomy == Komodo dragons were first documented by Europeans in 1910, when rumors of a "land crocodile" reached Lieutenant van Steyn van Hensbroek of the Dutch colonial administration. Widespread notoriety came after 1912, when Peter Ouwens, the director of the Zoological Museum of Bogor, Java, published a paper on the topic after receiving a photo and a skin from the lieutenant, as well as two other specimens from a collector. The first two live Komodo dragons to arrive in Europe were exhibited in the Reptile House at London Zoo when it opened in 1927. Joan Beauchamp Procter made some of the earliest observations of these animals in captivity and she demonstrated their behaviour at a scientific meeting of the Zoological Society of London in 1928.
=== New generation fuel === The aim of Guy Reinaud's project is to reply to the needs, in renewable domestic energy, of a population of 2 billion individuals living in the tropical regions of Africa, Latin America and Asia, and at the same time fighting against deforestation and climatic changes. The proposed solution is biomass charcoal as a source of renewable energy - patented and developed by Pro-Natura International. Biomass charcoal produces domestic energy from non-upgraded biomass, other than wood, in particular agricultural residues non-consumed by animals. By reducing the dependence on wood, biomass charcoal protects forests and as a consequence fights against desertification. Moreover, the energy produced by biomass charcoal is equal to that of wood charcoal for a sales price per kilo 50% cheaper.
Their communiqué emphasised quality jobs, decent work, artificial intelligence training, labour mobility and labour standards in critical mineral supply chains. The ministers announced a G7 conference on labour mobility and career progression in Paris in December 2026.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.